TransMedics to Report Second Quarter 2022 Financial Results on August 1, 2022
TransMedics Group, Inc. (TMDX) will release its financial results for the second quarter of 2022 on August 1, 2022, after market close. A conference call will follow at 4:30 p.m. ET, allowing investors to gain insights into the company’s performance and future strategies. TransMedics specializes in portable organ perfusion and assessment technologies, aiming to enhance organ transplantation for patients with end-stage organ failure. The company is dedicated to addressing organ shortages and improving transplant outcomes.
- Leadership in portable extracorporeal warm perfusion technology enhances market position.
- Focus on increasing organ utilization supports long-term growth potential.
- None.
ANDOVER, Mass., July 18, 2022 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the second quarter of 2022 after market close on Monday, August 1, 2022. The TransMedics management team will host a corresponding conference call beginning at 4:30 p.m. ET / 1:30 p.m. PT.
Investors interested in listening to the conference call may do so by dialing (844) 200-6205 for domestic callers or (929) 526-1599 for international callers, followed by Conference ID: 626851. A live and archived webcast of the event will be available on the "Investors" section of the TransMedics website at https://investors.transmedics.com/.
TransMedics is the world's leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Headquartered in Andover, Massachusetts, the company was founded to address the unmet need for more and better organs for transplantation and has developed technologies to preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the treatment of end-stage heart, lung, and liver failure.
Investor Contact:
Brian Johnston
332-895-3222
Investors@transmedics.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/transmedics-to-report-second-quarter-2022-financial-results-on-august-1-2022-301587302.html
SOURCE TransMedics Group, Inc.
FAQ
When will TransMedics report their Q2 2022 earnings?
What time is the TransMedics Q2 2022 earnings call?
How can I listen to the TransMedics earnings call?
Where can I find the webcast of the TransMedics earnings call?
